Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus acidophilus (Tanta University)
- Development stage
- Unknown
- Lead developer
- Tanta University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus acidophilus (Tanta University) is a live biotherapeutic product being investigated as an adjunctive therapy for children with drug-resistant epilepsy (DRE). Developed by Tanta University, this probiotic is administered orally. Clinical studies suggest that gut microbial imbalance (dysbiosis) may be a causative factor in epilepsy. This therapy aims to restore the equilibrium of the gut microbiota. A Phase 2 clinical trial showed that supplementation with Lactobacillus acidophilus significantly reduced seizure frequency and improved quality of life in pediatric patients with DRE. The mechanism is believed to involve the reduction of systemic inflammation, as evidenced by decreased serum levels of inflammatory markers such as HMGB1, NLRP3, and IL-1β. Preclinical models also suggest that Lactobacillus probiotics may influence brain function through the modulation of GABA.
- Other names
- lactobacillus-Tanta University-epilepsy (drug resistant)
Beyond the preview
Go deeper on Lactobacillus acidophilus (Tanta University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus acidophilus (Tanta University).